Nationwide trends in diagnosed sedative, hypnotic or anxiolytic use disorders in adolescents and young adults enrolled in Medicaid: 2001–2019
Addiction · 2025
DOI: 10.1111/add.16749 ↗Kurz gefasst
Fachartikel in der Zeitschrift Addiction, 2025. Verfasst von Greta Bushnell und 6 weiteren Autor:innen. Beteiligte Einrichtung: Center for Pharmacoepidemiology and Treatment Science, Rutgers Institute for Health, Health Care Policy and Aging Research, New Brunswick, NJ, USA. Hauptthemen laut MEDLINE: Medicaid, Hypnotics and Sedatives, Anti-Anxiety Agents, Substance-Related Disorders. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDA NIH HHS, National Institute on Drug Abuse.
Abstract (Originalsprache)
Background and Aim Sedative, hypnotic or anxiolytic use disorders (SHA‐UD) are defined by significant impairment or distress caused by recurrent sedative, hypnotic or anxiolytic use. This study aimed to measure trends in the prevalence of SHA‐UD diagnoses in adolescent and young adult US Medicaid enrollees from 2001 to 2019.
Design
Annual, cross‐sectional study, 2001–2019.
Setting
Medicaid Analytic eXtracts (MAX) and Transformed Medicaid Analytic Files (TAF) from 42 US states with complete data. Participants/Cases Adolescents (13–17 years) and young adults (18–29 years) with ≥10 months Medicaid enrollment in the calendar year; analytic sample contained 5.7 (2001) to 13.2 (2019) million persons per year.
Measurements
Annual prevalence of SHA‐UD in adolescent and young adult Medicaid enrollees [defined as an inpatient or outpatient ICD code (304.1x, 305.4x, F13.1x, F13.2x) in the calendar year] was stratified by sex, race/ethnicity, receipt of a benzodiazepine, z‐hypnotic or barbiturate prescription, and selected mental health diagnoses. Absolute and relative percent‐changes from 2001 vs. 2019 were summarized. Secondary analyses were restricted to states with more consistent data capture.
Findings
The prevalence of SHA‐UD diagnoses statistically significantly increased for adolescents (0.01% to 0.04%) and young adults (0.05% to 0.24%) from 2001 to 2019. Increasing trends were observed in sex and race/ethnicity subgroups, with greatest relative increases among Non‐Hispanic Black (624%) and Hispanic (529%) young adults. The trend increased among those with and without a benzodiazepine, z‐hypnotic or barbiturate prescription; i.e. young adults with (2001 = 0.39% to 2019 = 1.77%) and without (2001 = 0.03% to 2019 = 0.18%) a prescription. Most adolescents (76%) and young adults (91%) with a SHA‐UD diagnosis in 2019 had a comorbid substance use disorder.
Conclusions
Sedative, hypnotic or anxiolytic use disorders (SHA‐UD) diagnoses increased 3‐ to 5‐fold between 2001 and 2019 for adolescent and young adult US Medicaid enrollees, with prevalence remaining low in adolescents. The increase over two decades may be attributed to changes in the availability, use and misuse of sedative, hypnotic and anxiolytic medications and to increased detection, awareness and diagnosing of SHA‐UD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Pharmacoepidemiology and Treatment Science, Rutgers Institute for Health, Health Care Policy and Aging Research, New Brunswick, NJ, USA.
- Department of Biostatistics and Epidemiology, Rutgers University School of Public Health, Piscataway, NJ, USA.
- Department of Epidemiology, Columbia University Mailman School of Public Health, New York, NY, USA.
- Department of Psychiatry, Columbia University Irving Medical Center, New York, NY, USA.
- Department of Pharmacy Practice and Administration, Ernest Mario School of Pharmacy, Rutgers University, New Brunswick, NJ, USA.
- Center for Opioid Epidemiology and Policy, Department of Population Health, New York University School of Medicine, New York, NY, USA.
ORCID-Profile: Greta Bushnell, Magdalena Cerdá, Deborah Hasin
Förderung
- NIDA NIH HHS
- National Institute on Drug Abuse
Zitieren
APA
Bushnell, G., Lloyd, K., Olfson, M., Gerhard, T., Keyes, K., Cerdá, M., & Hasin, D. (2025). Nationwide trends in diagnosed sedative, hypnotic or anxiolytic use disorders in adolescents and young adults enrolled in Medicaid: 2001–2019. Addiction. https://doi.org/10.1111/add.16749
Vancouver
Bushnell G, Lloyd K, Olfson M, Gerhard T, Keyes K, Cerdá M, et al. Nationwide trends in diagnosed sedative, hypnotic or anxiolytic use disorders in adolescents and young adults enrolled in Medicaid: 2001–2019. Addiction. 2025. doi:10.1111/add.16749
BibTeX
@article{Bushnell2025,
author = {Bushnell, Greta and Lloyd, Kristen and Olfson, Mark and Gerhard, Tobias and Keyes, Katherine and Cerdá, Magdalena and Hasin, Deborah},
title = {Nationwide trends in diagnosed sedative, hypnotic or anxiolytic use disorders in adolescents and young adults enrolled in Medicaid: 2001–2019},
journal = {Addiction},
year = {2025},
doi = {10.1111/add.16749}
}
EUVIMED